How GLP-1s, Wegovy, Zepbound are reshaping the economy

Eternalcreative | Istock | Getty Images Miracle drugs, obesity treatments and skinny jabs. Call them what you will, few drugs have had a more transformative effect on Wall Street and waistlines over recent decades than GLP-1s. Familiarly known under the brand names Wegovy and Zepbound, Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medication used to…

Read More

Omada (OMDA) Q2 2025 earnings

The Omada Health logo is displayed on a smartphone screen. Sopa Images | Lightrocket | Getty Images Omada Health reported quarterly results for the first time since its initial public offering in June. Here’s how the company did based on average analysts’ estimates compiled by LSEG: Loss per share: 24 cents Revenue: $61 million vs. $55.2…

Read More

Eli Lilly (LLY) Q2 2025 earnings report

Eli Lilly on Thursday hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company raised its fiscal 2025 sales guidance to $60 billion to $62 billion, from a previous outlook of $58 billion to $61 billion on underlying strength across its business….

Read More

Trump administration to pilot covering obesity drugs

A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. For…

Read More